GLP-1 and dual GIP/GLP-1 receptor agonists in overweight/obese patients for atherosclerotic cardiovascular disease prevention: Where are we now?

J Diabetes Complications. 2023 Dec;37(12):108647. doi: 10.1016/j.jdiacomp.2023.108647. Epub 2023 Nov 7.

Authors

Emir Muzurović¹, Volkan Demirhan Yumuk², Manfredi Rizzo³

Affiliations

¹ Department of Internal Medicine, Endocrinology Section, Clinical Centre of Montenegro, Podgorica, Montenegro; Faculty of Medicine, University of Montenegro, Podgorica, Montenegro. Electronic address: dremir@t-com.me.
² Division of Endocrinology, Metabolism and Diabetes, Istanbul University Cerrahpaşa Medical Faculty, Istanbul 34452, Turkiye.
³ Faculty of Medicine, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Italy; Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates.

PMID: 37952274
DOI: 10.1016/j.jdiacomp.2023.108647

No abstract available

Keywords: Atherosclerotic cardiovascular disease; Dual glucagon-like peptide 1/gastric inhibitory peptide receptor agonists; Glucagon-like peptide 1 receptor agonists; Obesity; Overweight.

Publication types

Editorial

MeSH terms

Cardiovascular Diseases* / epidemiology
Cardiovascular Diseases* / prevention & control
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Gastric Inhibitory Polypeptide
Glucagon-Like Peptide 1
Glucagon-Like Peptide-1 Receptor / agonists
Humans
Obesity / complications
Overweight / complications

Substances

Glucagon-Like Peptide 1
Glucagon-Like Peptide-1 Receptor
Gastric Inhibitory Polypeptide